BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pulmozyme dornase alfa infectious data

The double-blind, U.K. MIST2 trial in 210 patients with pleural infection showed that intrapeural Pulmozyme plus tissue plasminogen activator (tPA) for 3 days significantly reduced mean pleural opacity, the primary endpoint, as measured by the percentage of the ipsilateral hemithorax occupied by effusion on...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >